Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-26T22:19:05.109Z Has data issue: false hasContentIssue false
  • English
  • Français

Impact of quetiapine in the treatment of insomnia associated with addictive pathologies: a retrospective study

Published online by Cambridge University Press:  16 April 2020

A. Teran  and
S. Majadas
A. Teran
Affiliation:
Ambulatory Drug Assistance Device, Complejo Asistencial San Juan de Dios, Palencia, Spain
S. Majadas
Affiliation:
AstraZeneca CNS, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Sleep disturbances are often present in addictive disorders. The atypical antipsychotic quetiapine has a favourable tolerability profile, mild sedative properties and a non addictive profile what makes it a suitable agent to investigate its potential for the treatment of insomnia associated with substance addictions.

Objective:

To evaluate the effect of quetiapine for the treatment of insomnia in addictive pathologies.

Method:

Observational retrospective chart review of patients with diagnoses of substance addiction and insomnia (DSM-IV-TR) and who received quetiapine for the treatment of their sleep disorder. In and outpatients were included. Outcome was measured with the Spiegel Sleep Questionnaire (SSQ). Patients' compliance and adverse events were also collected.

Results:

53 clinical histories were reviewed. 73.6% were males and mean age was 31 years. Heroine (65.4%) was the most frequent drug of use followed by cocaine (19.2%). Mean dose of quetiapine was 62.4 mg/day (SD:35.9). 73.6% completed the treatment with quetiapine for 60 days. Initial severity of insomnia was 2.42±0.61 (mean; SD) as measured by the SSQ global score (n=42), improving to 4.07±0.69 (p<0.0001) after quetiapine treatment. All items of the questionnaire improved significantly (p<0.0015). The greatest improvement in sleep occurred in the first week of treatment (p<0.001). Compliance was >90% in 71.8% of patients. The most frequent side effect was dry mouth (34%).

Conclusion:

Quetiapine at low doses showed benefits on sleep in drug dependence subjects suffering from insomnia as measured by SSQ. Quetiapine was associated with a fast onset of response and maintenance of effect up to 60 days

Type
Poster Session 1: Alcoholism and Other Addictions
Information
European Psychiatry , Volume 22 , Issue S1: 15th AEP Congress - Abstract book - 15th AEP Congress , March 2007 , pp. S201 - S202
Copyright
Copyright © European Psychiatric Association 2007
Submit a response

Comments

No Comments have been published for this article.